Sex hormone levels and risk of breast cancer with estrogen plus progestin
Ghada N Farhat
Affiliations of authors San Francisco Coordinating Center, California Pacific Medical Center Research Institute, San Francisco, CA GNF, NP, SRC Faculty of Health Sciences, University of Balamand, Beirut, Lebanon GNF Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, CA RTC Division of Preventive Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA JEM Fred Hutchinson Cancer Research Center, Seattle, WA GA, AZL Department of Internal Medicine, University of California San Francisco, San Francisco, CA AH, DG Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA EV Department of Internal Medicine, University of California Davis, Sacramento, CA JSL Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA JAC Department of Internal Medicine, Ohio State University, Columbus, OH RJ Department of Preventive Medicine, Stony Brook University, Stony Brook, NY DL Department of Medicine, Emory University, Atlanta, GA LP Karmanos Cancer Institute, Wayne State University, Detroit, MI MSS
J Natl Cancer Inst 105:1496-503. 2013
..Although high endogenous sex hormone levels and estrogen plus progestin (E+P) therapy are associated with increased breast cancer risk, it is unknown whether pretreatment levels of sex hormones modify E+P effect on breast cancer...